{"id":"https://openalex.org/W4416627581","doi":"https://doi.org/10.1158/1078-0432.30706296","title":"Supplementary Figures S1-S5 from Lisaftoclax in Combination with Alrizomadlin Overcomes Venetoclax Resistance in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Preclinical Studies","display_name":"Supplementary Figures S1-S5 from Lisaftoclax in Combination with Alrizomadlin Overcomes Venetoclax Resistance in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Preclinical Studies","publication_year":2025,"publication_date":"2025-11-25","ids":{"openalex":"https://openalex.org/W4416627581","doi":"https://doi.org/10.1158/1078-0432.30706296"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.30706296","doi":"https://doi.org/10.1158/1078-0432.30706296","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.30706296","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"supplementary-materials","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/1078-0432.30706296","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5021773274","display_name":"Yifan Zhai","orcid":"https://orcid.org/0000-0003-1672-2262","observed_orcids":["https://orcid.org/0000-0003-1672-2262"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yifan Zhai","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-1672-2262","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110047891","display_name":"Qiuqiong Tang","orcid":"https://orcid.org/0000-0002-9164-6290","observed_orcids":["https://orcid.org/0000-0002-9164-6290"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Qiuqiong Tang","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-9164-6290","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074334301","display_name":"Douglas D. Fang","orcid":"https://orcid.org/0000-0002-0895-332X","observed_orcids":["https://orcid.org/0000-0002-0895-332X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Douglas D. Fang","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-0895-332X","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065668271","display_name":"Jing Deng","orcid":"https://orcid.org/0000-0003-3157-5723","observed_orcids":["https://orcid.org/0000-0003-3157-5723"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jing Deng","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-3157-5723","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022301199","display_name":"Kaixiang Zhang","orcid":"https://orcid.org/0000-0002-3666-8868","observed_orcids":["https://orcid.org/0000-0002-3666-8868"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kaixiang Zhang","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-3666-8868","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053150001","display_name":"Qixin Wang","orcid":"https://orcid.org/0000-0003-1525-4540","observed_orcids":["https://orcid.org/0000-0003-1525-4540"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Qixin Wang","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-1525-4540","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028456330","display_name":"Yan Yin","orcid":"https://orcid.org/0000-0003-1563-4666","observed_orcids":["https://orcid.org/0000-0003-1563-4666"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yan Yin","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-1563-4666","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051994266","display_name":"Chengcheng Fu","orcid":"https://orcid.org/0000-0001-8623-848X","observed_orcids":["https://orcid.org/0000-0001-8623-848X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Chengcheng Fu","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-8623-848X","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027546968","display_name":"Shengli Xue","orcid":"https://orcid.org/0000-0003-4609-616X","observed_orcids":["https://orcid.org/0000-0003-4609-616X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sheng-Li Xue","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-4609-616X","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028312727","display_name":"Na Li","orcid":"https://orcid.org/0000-0001-5930-412X","observed_orcids":["https://orcid.org/0000-0001-5930-412X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Na Li","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-5930-412X","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077134386","display_name":"Feng Zhou","orcid":"https://orcid.org/0000-0002-9034-7109","observed_orcids":["https://orcid.org/0000-0002-9034-7109"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Feng Zhou","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-9034-7109","affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5085723739","display_name":"Dajun Yang","orcid":"https://orcid.org/0000-0002-6027-3604","observed_orcids":["https://orcid.org/0000-0002-6027-3604"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Dajun Yang","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-6027-3604","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.88919997215271,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.88919997215271,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10294","display_name":"Cell death mechanisms and regulation","score":0.07029999792575836,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.018400000408291817,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/venetoclax-resistance","display_name":"venetoclax resistance","score":0.996999979019165},{"id":"https://openalex.org/keywords/acute-myeloid-leukemia","display_name":"acute myeloid leukemia","score":0.9800000190734863},{"id":"https://openalex.org/keywords/acute-lymphoblastic-leukemia","display_name":"acute lymphoblastic leukemia","score":0.9990000128746033},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.5440000295639038},{"id":"https://openalex.org/keywords/synergistic-antitumor-effect","display_name":"synergistic antitumor effect","score":0.8550000190734863},{"id":"https://openalex.org/keywords/rs4","display_name":"RS4","score":0.8700000047683716},{"id":"https://openalex.org/keywords/mcl-1","display_name":"Mcl-1","score":0.7760000228881836},{"id":"https://openalex.org/keywords/bax","display_name":"Bax","score":0.7940000295639038},{"id":"https://openalex.org/keywords/bcl-xl","display_name":"Bcl-xL","score":0.7820000052452087},{"id":"https://openalex.org/keywords/p53","display_name":"p53","score":0.7350000143051147}],"concepts":[{"id":"https://openalex.org/C2779675984","wikidata":"https://www.wikidata.org/wiki/Q23671272","display_name":"Venetoclax","level":4,"score":0.8392999768257141},{"id":"https://openalex.org/C127561419","wikidata":"https://www.wikidata.org/wiki/Q224527","display_name":"Downregulation and upregulation","level":3,"score":0.8112000226974487},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6514000296592712},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.6197999715805054},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6108999848365784},{"id":"https://openalex.org/C81885089","wikidata":"https://www.wikidata.org/wiki/Q189082","display_name":"Cell culture","level":2,"score":0.4244999885559082},{"id":"https://openalex.org/C2779282312","wikidata":"https://www.wikidata.org/wiki/Q1956561","display_name":"Myeloid","level":2,"score":0.41119998693466187},{"id":"https://openalex.org/C2909962599","wikidata":"https://www.wikidata.org/wiki/Q180664","display_name":"Lymphoblastic Leukemia","level":3,"score":0.4009000062942505},{"id":"https://openalex.org/C114851261","wikidata":"https://www.wikidata.org/wiki/Q12147416","display_name":"Drug resistance","level":2,"score":0.36410000920295715},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.3474999964237213},{"id":"https://openalex.org/C190283241","wikidata":"https://www.wikidata.org/wiki/Q14599311","display_name":"Apoptosis","level":2,"score":0.3158000111579895},{"id":"https://openalex.org/C2994430510","wikidata":"https://www.wikidata.org/wiki/Q3270846","display_name":"Myeloid cells","level":3,"score":0.3116999864578247},{"id":"https://openalex.org/C2994294914","wikidata":"https://www.wikidata.org/wiki/Q1645075","display_name":"Acquired resistance","level":3,"score":0.3050999939441681},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.2985999882221222},{"id":"https://openalex.org/C3020616263","wikidata":"https://www.wikidata.org/wiki/Q1216998","display_name":"Tumor cells","level":2,"score":0.28700000047683716}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1158/1078-0432.30706296","doi":"https://doi.org/10.1158/1078-0432.30706296","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.30706296","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"pmh:oai:figshare.com:article/30706296","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/journal_contribution/Supplementary_Figures_S1-S5_from_Lisaftoclax_in_Combination_with_Alrizomadlin_Overcomes_Venetoclax_Resistance_in_Acute_Myeloid_Leukemia_and_Acute_Lymphoblastic_Leukemia_Preclinical_Studies/30706296","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.30706296","doi":"https://doi.org/10.1158/1078-0432.30706296","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.30706296","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.98580002784729,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4306247913","https://openalex.org/W4361954344","https://openalex.org/W4200363261","https://openalex.org/W4409631197","https://openalex.org/W4282920538","https://openalex.org/W4405050187","https://openalex.org/W7216099795","https://openalex.org/W7215717337","https://openalex.org/W3113500289","https://openalex.org/W4417016048"],"abstract_inverted_index":{"Supplementary":[0,16,33,57,68],"Figure":[1,17,34,58,69],"1.":[2],"Synergistic":[3,71],"antitumor":[4],"activity":[5,73],"of":[6,37,43,61,74],"lisaftoclax":[7,48,78],"combined":[8,49,75],"with":[9,50,77,87],"alrizomadlin":[10,51,80],"in":[11,25,31,52,81],"AML":[12],"CDX":[13,29],"mouse":[14],"models.":[15],"2.":[18],"Mean":[19],"plasma":[20],"and":[21,39,41,45,79,90],"tumor":[22],"drug":[23],"concentrations":[24],"a":[26],"subcutaneous":[27],"OCI-AML-3":[28],"model":[30],"mice.":[32],"3.":[35],"Upregulation":[36],"P53":[38],"BAX":[40],"downregulation":[42],"MCL-1":[44],"BCL-xL":[46],"by":[47],"RS4;11cells":[53],"expressing":[54,64,94],"BCL-2G101V":[55],"mutation.":[56],"4.":[59],"Characterization":[60],"RS4;11":[62,83,85,92],"cells":[63,86,93],"BCL-2":[65,95],"resistant":[66],"mutants.":[67,96],"5.":[70],"antiproliferative":[72],"treatment":[76],"parental":[82],"cells,":[84],"WT":[88],"BCL-2,":[89],"venetoclax-resistant":[91]},"counts_by_year":[],"updated_date":"2026-11-09T13:22:03.289127","created_date":"2025-11-25T00:00:00"}